Search

弥漫大B细胞淋巴瘤 (DLBCL) 是常见的非霍奇金淋巴瘤亚型, 其异质性高, 目前主要依靠病理学检查进 行诊断, 通过影像学检查及临床特征判定疗效及预后, 尚不能满足临床需求。循环肿瘤DNA (ctDNA) 是患者循环中 的肿瘤DNA游离片段, 作为新兴的特异性生物标志物, 在疾病辅助诊断、疗效评价、预后评估、治疗指导等方面展现 出易全程获取、携带全面信息、可动态实时监测等诸多优势, 尤其在与机器学习方法结合后, 可实现更为经济高效的 动态监测, 从而改善 DLBCL 的全程管理。通过监测疾病全程中的ctDNA水平可指导临床调整治疗方案, 实现DLBCL 患者个体化精准治疗管理。ctDNA 有望在未来成为一种可靠且广泛适用的生物标志物。 [ABSTRACT FROM AUTHOR]

本文报道采用560℃低温二次液相外延及精心光刻腐蚀,使外延片质量提高,器件的光电特性得到改善。最低I（?）h=1.7mA,外微分量子效率η=25%（单面）,最高连续激射温度为130℃,最大输出功率超过30mW。并采用PbSn焊料改进制管工艺,提高了器件的可靠性。

Copyright of Food & Fermentation Industries is the property of Food & Fermentation Industries and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Science Technology & Engineering is the property of Chinese Society of Technology Economics and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of China Surfactant Detergent & Cosmetics (1001-1803) is the property of China Surfactant Detergent & Cosmetics Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of China Surfactant Detergent & Cosmetics (1001-1803) is the property of China Surfactant Detergent & Cosmetics Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of China Surfactant Detergent & Cosmetics (1001-1803) is the property of China Surfactant Detergent & Cosmetics Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of China Surfactant Detergent & Cosmetics (1001-1803) is the property of China Surfactant Detergent & Cosmetics Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of China Surfactant Detergent & Cosmetics (1001-1803) is the property of China Surfactant Detergent & Cosmetics Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of China Surfactant Detergent & Cosmetics (1001-1803) is the property of China Surfactant Detergent & Cosmetics Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the utilization of proton pump inhibitors (PPIs) in the patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in the former General Hospital of Chengdu Military Command, and also to evaluate its rational utilization. Methods: A retrospective analysis was made on such indicators as application rate, duration of medication on the average per person, drug categories, frequency of medication (DDDs), use density (UD) and drug utilization index (DUI) of PPIs in NSTE-ACS patients of the hospital from January 2013 to June 2015. Rationality of PPIs application was also evaluated in accordance with the European and US guidelines. Results: Anti-platelet therapy was given to all the 129 patients, of whom 122 received dual anti-platelet therapy (DAPT ). There were 49 patients with moderate or high risks of CRUSADE bleeding scores, accounting for 37.98%, and bleeding risk was (11.00 ± 3.88)%. The application rate, the drug category, the duration of medication on the average per person, UD and DUI of PPIs were 90.70%, (1.32 ± 0.57), (7.05 ± 4.63) days, 129.15 DDDs and 1.71, respectively. For the application rate and DDDs, the top 3 were pantoprazole, esomeprazole and lansoprazole, and for DUI the top 3 were omeprazole, esomeprazole and pantoprazole. There was excessive use of PPIs in most patients. Conclusion: For the application of PPIs in the NSTE-ACS patients of the hospital, many problems existed, such as high rate of application, improper selection of drug categories and excessive utilization of drugs, which should be brought under control. [ABSTRACT FROM AUTHOR]

Objective To explore the relationship between the methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and H-type hypertension.Methods A total of 273 consecutive patients with hypertension,including185 cases of patients with H-type hypertension (observation group,Hcy≥10 μmol/L) and 88 cases of patients with nonH-type hypertension (control group),were enrolled.We collected the fasting venous blood in the two groups,then,the MTHFR C677T gene polymorphism was observed by PCR-RFLP.The relationships between the genotypes of MTHFR C677T and H-type hypertension were analyzed by Logistic regression.Results There were 31 and 35 cases of MTHFR C677T CC genotype in the observation group and control group,and the number of CT genotype was 104 and 45,respectively; the number of TT genotype was 50 and 8,respectively; the number of C allele of the two groups was 166 and 115,respectively; the number of T allele of the two groups was 204 and 61,respectively; Significant difference was found in the distribution of the allelic frequencies of T and C,and CC and TT genotypes between the two groups (P < 0.01).Logistic regression analysis showed that MTHFR C677T genotype mutation (OR = 2.645,95% CI: 1.737-4.025,P < 0.01) was an independent risk factor for H-type hypertension.Conclusion MTHFR C677T genotype TT is an independent risk factor for H-type hypertension. [ABSTRACT FROM AUTHOR]